Cargando…

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting

BACKGROUND: Infliximab is a chimeric anti-tumor necrosis factor alpha (TNF-α) monoclonal antibody that ameliorates inflammation when it binds to and neutralizes TNF-α. It is often used in patients with Crohn’s disease and ulcerative colitis to reduce the severity of disease symptoms and induce disea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Checkley, L. Allyson, Kristofek, Loretta, Kile, Samantha, Bolgar, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394553/ https://www.ncbi.nlm.nih.gov/pubmed/30311152 http://dx.doi.org/10.1007/s10620-018-5319-6

Ejemplares similares

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Infliximab-Related Infusion Reactions: Systematic Review
por: Lichtenstein, Lev, et al.
Publicado: (2015)

Immediate-type infliximab infusion reaction presenting as purpura
por: Soong, Laura, et al.
Publicado: (2018)

Predictors of infusion reactions during infliximab treatment in patients with arthritis
por: Kapetanovic, Meliha C, et al.
Publicado: (2006)

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Development of anti-infliximab antibody is associated with reduced efficacy and infusion reaction in Behçet's disease with uveitis
por: Ishigatsubo, Y, et al.
Publicado: (2015)

Case Report: Infusion-Related Reactions to Intravenous Infliximab and Subcutaneous Ustekinumab in Pediatric Crohn's Disease
por: Kakiuchi, Toshihiko, et al.
Publicado: (2021)

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
por: Szymanska, Edyta, et al.
Publicado: (2021)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center
por: Park, Jiyeon Joy, et al.
Publicado: (2018)

Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis
por: Okuyama, Ayumi, et al.
Publicado: (2010)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions
por: Kelly, Maureen M., et al.
Publicado: (2019)

Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study
por: Wang, Xiaolei, et al.
Publicado: (2019)

Successful Treatment of Tolosa-Hunt Syndrome after a Single Infusion of Infliximab
por: Halabi, Tarek, et al.
Publicado: (2018)

Infliximab and Dexamethasone Attenuate the Ductular Reaction in Mice
por: Verhulst, Stefaan, et al.
Publicado: (2016)

Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit
por: Sandberg, Kelly C., et al.
Publicado: (2019)

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol
por: Ong, Wan Chee, et al.
Publicado: (2022)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions
por: Marais, Ben J, et al.
Publicado: (2020)

Infliximab is a plausible alternative for neurologic complications of Behçet disease
por: Zeydan, Burcu, et al.
Publicado: (2016)

Safety of Accelerated Infliximab Infusions in Children With Inflammatory Bowel Disease: A Retrospective Cohort Study
por: Jagt, Jasmijn Z., et al.
Publicado: (2023)

Merkel cell carcinoma in a young female on infliximab
por: Harrison, Alex, et al.
Publicado: (2022)

Accelerated Infliximab Infusion Safety and Tolerability Is Non-inferior to Standard Infusion Protocol in Inflammatory Bowel Disease Patients: A Randomized Controlled Study
por: Abushamma, Suha, et al.
Publicado: (2023)

Delayed Hypersensitivity Reaction to Infliximab Due to Mammalian Meat Allergy
por: González Polanco, Esthermari, et al.
Publicado: (2023)

Individualized treatment with infliximab therapy in children with Crohn’s disease support shorter time intervals between infusions
por: Sommar, M., et al.
Publicado: (2012)

Recurrent acute coronary syndrome after infliximab infusion in a patient with rheumatoid arthritis: Case report
por: Rebolledo Del Toro, Martin, et al.
Publicado: (2023)

Brentuximab Vedotin Infusion Reaction Management: A Case Study
por: Comer, Holly, et al.
Publicado: (2017)

1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
por: Simpson, Michelle, et al.
Publicado: (2022)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab
por: Scaldaferri, Franco, et al.
Publicado: (2017)

Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion
por: Vimpolsek, Maja, et al.
Publicado: (2019)

Management of infusion reactions associated with cetuximab treatment: A case report
por: Ohshita, Naohiro, et al.
Publicado: (2017)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar
por: Courville, Jocelyn, et al.
Publicado: (2021)

Infliximab as an alternative therapy for refractory adult onset Kawasaki disease: A case report
por: Kawaguchi, Takeshi, et al.
Publicado: (2018)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q48hecq4uje0boncfb3p6hc3jj